Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282411 · ClinicalTrials.gov registry record
Anatomic Outcomes Following Ozurdex Injections
A clinical trial, sponsored by Barnes Retina Institute.
- Completed
- Registry status
- 10
- Enrollment target
NCT01282411 is a clinical trial that has completed, run by Barnes Retina Institute. The registered enrollment target is 10 participants.
The verdict
NCT01282411 has completed, sponsored by Barnes Retina Institute.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
Ozurdex(TM) has recently been FDA approved for use in macular edema secondary to retinal vein occlusion. It remains unclear how quickly the drug works and for how long as the initial studies did not have frequent anatomic monitoring. This study will utilize frequent Spectral domain OCT imaging to better understand the onset of treatment effectiveness and duration of action on the anatomic thickness of the retina, in addition to distinguishing structural abnormalities of responders from non-responders.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01282411
The ClinicalTrials.gov registry entry for NCT01282411 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barnes Retina Institute, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01282411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01282411 about?
NCT01282411 is a clinical study titled "Anatomic Outcomes Following Ozurdex Injections". Ozurdex(TM) has recently been FDA approved for use in macular edema secondary to retinal vein occlusion. It remains unclear how quickly the drug works and for how long as the initial studies did not have frequent anatomic monitoring. This study will utilize frequent Spectral domain OCT imaging to be...
What is the current status of trial NCT01282411?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2010-02. Estimated completion is 2011-07.
Who is sponsoring clinical trial NCT01282411?
This trial is sponsored by Barnes Retina Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.